Floatz logo

tl-895

Relapsed/Refractory B Cell Malignancies

Telios Pharma, Inc.Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

48 Active assets in the Relapsed/Refractory B Cell Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
University Hospital, Basel, Switzerland
Phase 2BB
Zanubrutinib
Curis, Inc.
Phase 2BB
PREDNISONE TABLETS
Curis, Inc.
Phase 2BB
Inno-206
Curis, Inc.
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Curis, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

tl-895 is also rated in:

Mantle Cell Lymphoma and Diffuse Large B Cell LymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
COVID-19Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →